| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
BIASCA, Switzerland—In late March, Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, announced that its Swiss manufacturing company, Helsinn Advanced Synthesis SA, has won awards for the fourth year running in all categories at the 2018 CMO Leadership Awards. The awards, which recognize the leading contract manufacturing organizations, are based on customer feedback gathered by Industry Standard Research.
 
Helsinn won awards—in the overall and small pharma categories—for quality, reliability, capabilities, expertise, compatibility and service.
 
“It is a great honor for Helsinn to have been recognized for the fourth year running for the all-round quality of our manufacturing. Helsinn Advanced Synthesis is a cornerstone of Helsinn’s business and is also a highly-trusted partner for industry,” said Riccardo Braglia, Helsinn Group vice chairman and CEO. “Winning across all categories for another consecutive year is a great accomplishment, a testament to the quality and hard work of the staff.”
 
Added Waldo Mossi, Helsinn Advanced Synthesis’s general manager: “Our quality is our calling card, and the recognition of our peers is critical to our reputation. I would like to thank the outstanding team at Helsinn Advanced Synthesis for their reliably high-quality work and their relentless commitment.”

Related Topics

Published In

Volume 14 - Issue 5 | May 2018

May 2018

May 2018 Issue

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue